Avineuro

Avineuro is engaged in research and development of original drugs for the treatment of CNS disorders. The main focus of the company is psychiatric and neurological diseases, in particular schizophrenia, anxiety disorders, Parkinson’s disease, and metabolic disorders and obesity.

On 31 May 2023, the Russian Ministry of Health issued a certificate of registration for the medical use of the drug product AVIANDR® (INN: Maritupirdine) for treating generalised anxiety disorder and adjustment disorders, including those caused by COVID-19.

AVIANDR® has multi-target activity, inhibiting serotonin, adrenergic, dopamine and histamine receptors, and thus has anti-anxiety, anti-asthenic and antidepressant properties.

The results of multicentre, randomised, placebo-controlled trials (a total of 655 subjects participated in the trials) showed a rapid reduction in anxiety symptoms from the first week of taking the drug product. Patients did not experience drowsiness or other side effects (unemotionality, withdrawal syndrome, decreased libido) characteristic of most drug products used in therapy, which is important for patient compliance with the prescribed regimen (adherence). Anxiety is often accompanied by rapid heartbeat, fatigue, weakness, high blood pressure, sweating and abdominal pain, and AVIANDR® relieves these symptoms.

The drug product was developed with the support of the Russian Ministry of Industry and Trade under the NTI Neuronet roadmap. The entire development cycle, starting with the synthesis of the molecule, clinical research and production of the drug product, was carried out on the territory of the Russian Federation.